COR Cencora, Inc.
Wholesale-Drugs, Proprietaries & Druggists' Sundries · NYSE · SEC CIK 1140859 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.1%
TTM net income YoY38.3%
TTM EPS YoY38.3%
Revenue 3-yr CAGR9.4%
Net income 3-yr CAGR15.8%
Margins
Gross margin4.0%
Operating margin0.9%
Net margin0.8%
FCF margin1.2%
EBITDA margin1.2%
Returns
ROE104.3%
ROA3.3%
ROIC (approx.)22.3%
Asset turnover4.22x
Leverage & solvency
Liabilities / assets96.1%
Debt / equity3.84x
Current ratio0.93x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.84x
Accruals ratio-2.8%
Payout ratio17.8%
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-06-30 | 2026Q22026-03-31 | 2026Q12025-12-31 | 2025Q4*2025-09-30 | 2025Q32025-06-30 | 2025Q22025-03-31 | 2025Q12024-12-31 | 2024Q4*2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $84.75B | $78.36B | $85.93B | $83.73B | $80.66B | $75.45B | $81.49B | $79.05B |
| Cost of revenue | $81.15B | $74.77B | $82.86B | $80.77B | $77.76B | $72.39B | $78.93B | $76.56B |
| Gross profit | $3.61B | $3.59B | $3.07B | $2.95B | $2.91B | $3.06B | $2.56B | $2.49B |
| SG&A expense | $2.13B | $1.98B | $1.80B | $1.75B | $1.67B | $1.60B | $1.47B | $1.49B |
| Operating income | $1.12B | $1.14B | $760.45M | $18.50M | $867.65M | $1.04B | $706.25M | $126.64M |
| Pretax income | $996.39M | $2.09B | $708.64M | -$187.04M | $896.28M | $928.66M | $620.45M | $125.18M |
| Income tax | $219.73M | $459.04M | $142.51M | $146.03M | $206.53M | $211.24M | $126.73M | $117.71M |
| Net income | $763.52M | $1.64B | $559.65M | -$339.70M | $687.40M | $717.87M | $488.60M | $3.38M |
| EBITDA | $1.39B | $1.39B | $1.02B | $277.27M | $1.12B | $1.30B | $984.75M | $881.66M |
| EPS (basic) | 3.95 | 8.44 | 2.88 | — | 3.55 | 3.70 | 2.52 | — |
| EPS (diluted) | 3.94 | 8.40 | 2.87 | — | 3.52 | 3.68 | 2.50 | — |
| Dividends declared per share | 0.60 | 0.60 | 0.60 | 0.55 | 0.55 | 0.55 | 0.55 | 0.51 |
| Weighted avg. shares (diluted) | 193.94M | 195.38M | 195.32M | — | 195.23M | 195.09M | 195.19M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $2.82B | $2.18B | $1.75B | $4.36B | $2.23B | $1.98B | $3.22B | $3.13B |
| Receivables | $25.45B | $24.89B | $25.98B | $25.23B | $24.56B | $23.72B | $24.55B | $23.87B |
| Inventory | $21.03B | $20.01B | $24.08B | $20.49B | $20.14B | $18.97B | $20.51B | $19.00B |
| Current assets | $55.34B | $53.14B | $54.15B | $52.24B | $48.81B | $46.53B | $49.99B | $47.72B |
| PP&E, net | $2.84B | $2.81B | $2.45B | $2.54B | $2.43B | $2.30B | $2.10B | $2.18B |
| Goodwill | $16.52B | $16.45B | $13.73B | $13.68B | $14.33B | $14.09B | $9.18B | $9.32B |
| Intangibles | $5.93B | $6.05B | $3.68B | $3.77B | $3.93B | $3.86B | $3.68B | $4.00B |
| Total assets | $83.81B | $81.65B | $78.36B | $76.59B | $73.96B | $71.19B | $69.05B | $67.10B |
| Current liabilities | $59.20B | $56.13B | $59.13B | $57.82B | $53.96B | $53.33B | $54.51B | $54.28B |
| Short-term debt | $279.15M | $202.66M | $342.28M | $117.78M | $196.79M | $770.32M | $2.21B | $576.33M |
| Long-term debt | $11.44B | $12.18B | $7.58B | $7.54B | $8.04B | $7.09B | $5.94B | $3.81B |
| Total debt | $11.72B | $12.39B | $7.92B | $7.66B | $8.24B | $7.86B | $8.15B | $4.39B |
| Total liabilities | $80.57B | $78.07B | $76.27B | $74.84B | $71.75B | $70.01B | $68.69B | $66.31B |
| Shareholders' equity | $3.05B | $3.40B | $1.91B | $1.51B | $1.98B | $1.01B | $226.58M | $645.94M |
| Net debt | $8.91B | $10.21B | $6.17B | $3.30B | $6.01B | $5.88B | $4.92B | $1.26B |
| Shares outstanding | 190.83M | 194.56M | 194.52M | 193.94M | 193.86M | 193.78M | 193.85M | 194.94M |
| Cash flow statement | ||||||||
| Operating cash flow | $2.65B | $1.34B | -$2.31B | $3.13B | $109.25M | $3.35B | -$2.72B | $1.00B |
| Capital expenditure | $226.04M | $165.62M | $119.38M | $249.81M | $183.22M | $129.06M | $105.89M | $182.32M |
| Free cash flow | $2.43B | $1.17B | -$2.42B | $2.88B | -$73.97M | $3.22B | -$2.82B | $818.05M |
| Investing cash flow | -$240.15M | -$4.87B | -$299.31M | -$321.94M | -$234.69M | -$4.08B | -$343.04M | -$241.88M |
| Financing cash flow | -$1.77B | $3.98B | $43.20M | -$683.78M | $215.48M | -$491.74M | $3.21B | -$957.26M |
| Depreciation & amortization | $269.50M | $249.29M | $260.40M | $258.77M | $254.00M | $259.82M | $278.49M | $755.02M |
| Stock-based compensation | $28.73M | $28.00M | $66.05M | $25.94M | $23.18M | $28.45M | $70.38M | $34.59M |
| Dividends paid | $116.59M | $117.46M | $126.52M | $107.51M | $107.49M | $111.19M | $110.89M | $100.94M |
| Share buybacks | — | — | — | $71,000 | $0 | $50.00M | $385.40M | $504.98M |
Free plan shows the latest 8 periods; Pro shows all 73 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.